Vicore Pharma Holding AB VICO

STOCKHOLM, SE / ACCESS Newswire / September 30, 2026 / AB (STO:VICO)(NASDAQ:VCRE), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists, today announced that the number of Vicore shares and votes has increased following the exercise of warrants with subsequent delivery of shares to participants in the incentive programs Board LTIP 2023, Board LTIP 2024 and Board RSU 2025. The shares were issued through the exercise of 117,737 share awards, which are

STOCKHOLM, SE / ACCESS Newswire / September 17, 2026 / AB (publ) (STO:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists, today announced that the company will participate in the Stifel 2026 Virtual Immunology and Inflammation Forum.Location: VirtualFormat: Presentation and 1×1 meetingsPresentation Date and Time: Thursday, September 24, 2026, 8:30-8:55 AM ETParticipants: Ahmed Mousa, CEO; Hans

STOCKHOLM, SE / ACCESS Newswire / July 7, 2026 / Vicore Pharma Holding AB (NASDAQ Stockholm:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), ...

LONDON, July 06, 2026--Citi Issuer Services, acting through Citibank N.A., has been appointed by Vicore Pharma Holding AB ("Vicore Pharma"), a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF), to act as Depositary Bank for its sponsored Level 2 American Depositary Receipt ("ADR") program.

STOCKHOLM, SE / ACCESS Newswire / July 6, 2026 / Vicore Pharma Holding (STO:VICO) - Dr. Slack brings over 20 years' experience in fibrosis and respiratory translational science and joins from GSK, where he served as Vice President and Head of Respiratory ...

STOCKHOLM, SE AND CAMBRIDGE, MA / ACCESS Newswire / July 1, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO)(Nasdaq US:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type ...

STOCKHOLM, SE AND CAMBRIDGE, MA / ACCESS Newswire / June 2, 2026 / Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 (AT2) receptor agonists, today announced that the company will host a ...

STOCKHOLM, SE / ACCESS Newswire / May 26, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 (AT2) receptor agonists, today announced participation in the Jefferies Global ...

Proposed dual listing expected to broaden access to US investors as buloxibutid advances toward its Phase 2b readout in IPF, with no concurrent financing or share offering planned STOCKHOLM, SWEDEN AND CAMBRIDGE, MA / ACCESS Newswire / May 22, 2026 ...

Appointment strengthens Vicore's board with nearly four decades of global pharmaceutical leadership as the company advances buloxibutid toward an important late-stage data readout STOCKHOLM, SE / ACCESS Newswire / May 7, 2026 /Vicore Pharma Holding ...

STOCKHOLM, SE / ACCESS Newswire / May 6, 2026 /Today on 6 May 2026, the Annual General Meeting (the "AGM") of Vicore Pharma Holding AB (publ) ("Vicore Pharma" or the "Company")(STO:VICO) was held, whereby the shareholders passed the following resolutions. ...

STOCKHOLM, SE / ACCESS Newswire / May 6, 2026 / Vicore Pharma Holding AB (STO:VICO) ("Vicore"), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), publishes the interim report for the first quarter ...

STOCKHOLM, SE / ACCESS Newswire / April 29, 2026 /Vicore Pharma Holding AB (Nasdaq Stockholm:VICO), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today ...

The randomized Phase 2b ASPIRE trial successfully completed planned enrollment of over 360 patients, reflecting strong execution and robust site engagement ASPIRE is designed to assess the effect of buloxibutid on forced vital capacity (FVC) over ...